Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?

Simply Wall St.02-04

Ascletis Pharma recently filed a follow-on equity offering of HK$843.54 million via a subsequent direct listing, issuing 69,256,000 ordinary shares at HK$12.18 each. The fundraising follows positive ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment